NCT00329927View on ClinicalTrials.gov

Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Elderly Subjects

PHASE2CompletedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

June 30, 2006

Conditions

Influenza

Interventions

BIOLOGICAL

Surface Antigen, Inactivated, (Adjuvanted with MF59C.1), form. 2006-07

Trial Locations (2)

66100

Dipartimento di Medicina e Scienze dell'Invecchiamento, Università G. D'Annunzio, Via Dei Vestini

Unknown

Ufficio Igiene e Sanità Pubblica di Lanciano, Via S. Spaventa, 37, Lanciano

Sponsors

Lead Sponsor

Collaborators (1)

Novartis Vaccines

All Listed Sponsors

collaborator

Novartis Vaccines

INDUSTRY

lead

Novartis

INDUSTRY